SmithJ.W.Therapeutic apheresis in the United States: current indications and directions (editorial).Ther Apher1999; 3(1): 1–3.
2.
LockwoodC.M., PinchingA.J., SwenyP.Plasmaexchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis.Lancet1977; 1(8002): 63–7.
3.
RossenR.D., HershE.M., SharpJ.T.Effect of plasma exchange on circulating immune complexes and antibody formation in patients treated with cyclophosphamide and prednisone.Am J Med1977; 63(5): 674–82.
4.
JonesJ.V., CummingR.H., BucknallR.C., AsplinC.M.Plasmapheresis in the management of acute systemic lupus erythematosus?Lancet1976; 1(7962): 709–711.
5.
FurlanM., RoblesR., GalbuseraM., RemuzziG.von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.N Engl J Med1998; 339(22): 1578–84.
6.
RockG., PortaC., Bobbio-PallaviciniE.Thrombotic thrombocytopenic purpura treatment in year 2000.Haematologica2000; 85(4): 410–9.
7.
MaticG., HofmannD., WinklerR.Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption.Artif Organs2000; 24(2): 103–7.
8.
MaticG., SchuttW., WinklerR.E., TiessM., RamlowW.Extracorporeal removal of circulating immune complexes: from non-selective to patient-specific.Blood Purif2000; 18(2): 156–60.
9.
EsnaultV.L., TestaA., JayneD.R., SoulillouJ.P., GuenelJ.Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis.Nephron1993; 65(2): 180–4.
10.
PalmerA., CairnsT., DischeF.Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide.Nephrol Dial Transplant1991; 6(8): 536–42.
11.
SueokaA.Present status of apheresis technologies, part 3: adsorbent.Ther Apher1997; 1(3): 271–83.
12.
SchneiderK.M.Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy.Kidney Int1998; 64(suppl): S61–5.
13.
BraunN., RislerT.Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease.Ther Apher1999; 3(3): 240–5.
14.
ValbonesiM., GarelliS., MontaniF., CefisM., RossiU.Management of immune-mediate and paraproteinemic diseases by membrane plasma separation and cascade filtration.Vox Sang1982; 43(2): 91–101.
15.
NoseY., YamajiK., SueokaA., YamaneS.Membrane apheresis technology: historical perspective and new trends toward bioincompatible systems (editorial).Ther Apher1997; 1(1): 5–12.
16.
SueokaA.Present status of apheresis technologies: Part 2.Membrane plasma fractionator (editorial). Ther Apher1997; 1(2): 135–46.
17.
SiamiG.A., SiamiF.S.Cryofiltration apheresis in the United States.Ther Apher1998; 2(3): 228–35.
18.
BennyW.B., SuttonD.M., OgerJ., BrilV., McAteerM.J., RockG.Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients.Transfusion1999; 39(7): 682–7.
19.
HigginsR.M., BevanD.J., CareyB.S.Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation.Lancet1996; 348(9036): 1208–11.
20.
FreiburghausC., BerntorpE., EkmanM., GunnarssonM., KjellbergB., NilssonI.M.Tolerance induction using the Malmo treatment model 1982–1995.Haemophilia1999; 5(1): 32–9.
21.
StegmayrB.G., AlmrothG., BerlinG.Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis.A Swedish multi-center study. Int J Artif Organs1999; 22(2): 81–7.
22.
HoweR.B., ChristieD.J.Protein A immunoadsorption treatment in hematology: an overview.J Clin Apheresis1994; 9(1): 31–2.
23.
FennellyD.W., NortonL., SznolM., HakesT.B.A phase II treatment of extracorporeal plasma immunoadsorption of patient plasma with Prosorba columns for treating metastatic breast cancer.Cancer1995; 75(8): 2099–102.
24.
MesserschmidtG.L., HenryD.H., SnyderH.W.Jr.Protein A immunoadsorption in the treatment of malignant disease.J Clin Oncol1988; 6(2): 203–12.
25.
FelsonD.T., LaValleyM.P., BaldassareA.R.The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial.Arthritis Rheum1999; 42(10): 2153–9.
26.
HehmkeB., SalzsiederE., MaticG.B., WinklerR.E., TiessM., RamlowW.Immunoadsorption of immunoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune diseases.Ther Apher2000; 4(4): 296–302.
27.
HiepeF., PfullerB., WolbartK.C1q: a multifunctional ligand for a new immunoadsorption treatment.Ther Apher1999; 3(3): 246–51.
28.
EilA., MaticG., DrobnikW.Safety and Kinetics of the C1q-Adsorber. 2nd international Congress of the International Society for Apheresis, Saarbrücken, 1999 (abstract).
